Glucosio S.A.L.F. (Glucose Monohydrate)

Glucosio S.A.L.F. is employed in clinical settings where rapid glucose supplementation or fluid balance is required.

• Treatment of documented hypoglycemia when oral glucose is not feasible.
• Component of parenteral nutrition regimens for patients unable to receive enteral feeding.
• Support for fluid and electrolyte replacement in perioperative or trauma care.
• Provision of an energy substrate during prolonged fasting or critical illness.
• Adjunct in neonatal intensive care to maintain glucose homeostasis.
• Use in surgical patients to prevent peri‑operative hypoglycemia.

Adverse reactions to Glucosio S.A.L.F. are generally related to the glucose load and the route of administration.

Common

• Transient hyperglycemia, especially in patients with impaired insulin response.
• Local irritation or pain at the injection site.
• Mild nausea or vomiting following rapid infusion.
• Electrolyte shifts such as mild hyponatremia due to osmotic effects.
• Headache associated with rapid changes in blood glucose.

Serious

• Severe hyperglycemia leading to osmotic diuresis.
• Allergic or anaphylactic reaction to excipients.
• Volume overload causing pulmonary edema in susceptible individuals.
• Severe hypoglycemia if glucose is administered after insulin without monitoring.
• Life‑threatening electrolyte disturbances (e.g., severe hyponatremia).

When using Glucosio S.A.L.F., clinicians should observe several precautions to minimize risk and ensure appropriate therapy.

• Verify blood glucose level before and after administration to avoid over‑correction.
• Adjust dose in patients with renal or hepatic impairment due to altered glucose metabolism.
• Monitor fluid balance closely in patients at risk for volume overload or heart failure.
• Use caution in individuals with known hypersensitivity to any component of the solution.
• Limit infusion rate according to manufacturer guidelines to reduce the chance of hyperglycemia.
• Consider alternative carbohydrate sources for patients with uncontrolled diabetes mellitus.
• Ensure aseptic technique to prevent contamination of the injection solution.

Glucosio S.A.L.F. may interact with other medications or clinical conditions that affect glucose homeostasis or fluid balance.

Avoid

• Concomitant use of high‑dose insulin without glucose monitoring, which can precipitate severe hypoglycemia.
• Co‑administration with other hypertonic glucose solutions, increasing risk of hyperglycemia and osmotic complications.
• Use with diuretics in patients prone to electrolyte disturbances without close monitoring.

Use with caution

• Concurrent administration of corticosteroids, which can raise blood glucose levels.
• Beta‑blockers that may mask symptoms of hypoglycemia.
• Medications that affect renal function, such as ACE inhibitors, requiring careful fluid assessment.
• Anticoagulants, as rapid infusion may affect coagulation parameters.
• Drugs that alter electrolyte balance, like potassium‑sparing agents.